The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects
Open accessAbstract
Background: Cytotoxic T‐lymphocyte antigen 4 (CTLA‐4) is a negative immune regulator. Heterozygous CTLA4 germline mutations can cause a complex immune dysregulation syndrome in human subjects. Objective: We sought to characterize the penetrance, clinical features, and best treatment options in 133 CTLA4 mutation carriers. Methods: Genetics, clinical features, laboratory values, and outcomes of treatment options were assessed in a worldwide cohort of CTLA4 mutation carriers. Results: We identified 133 subjects from 54 unrelated families carrying 45 different heterozygous CTLA4 mutations, including 28 previously undescribed mutations. Ninety mutation carriers were considered affected, suggesting a clinical penetrance of at least 67%; median age of onset was 11 years, and the mortality rate within affected mutation carriers was 16% (n = 15). Main clinical manifestations included hypogammaglobulinemia (84%), lymphoproliferation (73%), autoimmune cytopenia (62%), and respiratory (68%), gastrointestinal (59%), or neurological features (29%). Eight affected mutation carriers had lymphoma, and 3 had gastric cancer. An EBV association was found in 6 patients with malignancies. CTLA4 mutations were associated with lymphopenia and decreased T‐, B‐, and natural killer (NK) cell counts. Successful targeted therapies included application of CTLA‐4 fusion proteins, mechanistic target of rapamycin inhibitors, and hematopoietic stem cell transplantation. EBV reactivation occurred in 2 affected mutation carriers after immunosuppression. Conclusions: Affected mutation carriers with CTLA‐4 insufficiency can present in any medical specialty. Family members should be counseled because disease manifestation can occur as late as 50 years of age. EBV‐ and cytomegalovirus‐associated complications must be closely monitored. Treatment interventions should be coordinated in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187 · cited 2×
“In subjects presenting with immunodeficiency, autoimmunity, and lymphoproliferation with impaired Treg cell development or function, in addition to CTLA-4 insufficiency, also mutations in FOXP3,LRBA, IL2RA,FASL,FAS,PI3K,NFKB1,NFKB2, STAT3, and STAT5B should be considered as a differential diagnosis.(6,23,25-32) Mutati…”
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · cited 2×
“CTLA-4 binds these ligands with a higher affinity and avidity than CD28 and removes them from the surfaces of APCs through transendocytosis, resulting in reduction in APC-mediated activation of conventional T cells.(12,13) CTLA4 encodes for 4 exons: exon 1 encodes the signal peptide, exon 2 encodes the ligand-binding…”
Picard, C., Al-Herz, W., Bousfiha, A., Casanova, J.-L., Chatila, T., Conley, M. E., Cunningham-Rundles, C., Etzioni, A., Holland, S. M., Klein, C., et al. (2015) · Journal of Clinical Immunology · doi:10.1007/s10875-015-0201-1 · Cited by 1,197
Self-citationImmune dysregulation in human subjects with heterozygous germline mutations in CTLA4
Kuehn, H. S., Ouyang, W., Lo, B., Deenick, E. K., Niemela, J. E., Avery, D. T., Schickel, J.-N., Tran, D. Q., Stoddard, J., Zhang, Y., et al. (2014) · Science · doi:10.1126/science.1255904 · Cited by 848
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B.-S., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 832
Self-citationThe emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3108 · Cited by 786
Self-citationThe Interaction Properties of Costimulatory Molecules Revisited
Collins, A. V., Brodie, D. W., Gilbert, R. J. C., Iaboni, A., Manso-Sancho, R., Walse, B., Stuart, D. I., van der Merwe, P. A., & Davis, S. J. (2002) · Immunity · doi:10.1016/s1074-7613(02)00362-x · Cited by 684
Lo, B., Zhang, K., Lu, W., Zheng, L., Zhang, Q., Kanellopoulou, C., Zhang, Y., Liu, Z., Fritz, J. M., Marsh, R., et al. (2015) · Science · doi:10.1126/science.aaa1663 · Cited by 675
Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations
Milner, J. D., Vogel, T. P., Forbes, L., Ma, C. A., Stray-Pedersen, A., Niemela, J. E., Lyons, J. J., Engelhardt, K. R., Zhang, Y., Topcagic, N., et al. (2015) · Blood · doi:10.1182/blood-2014-09-602763 · Cited by 557
Self-citationDeleterious Mutations in LRBA Are Associated with a Syndrome of Immune Deficiency and Autoimmunity
Lopez-Herrera, G., Tampella, G., Pan-Hammarström, Q., Herholz, P., Trujillo-Vargas, C. M., Phadwal, K., Simon, A. K., Moutschen, M., Etzioni, A., Mory, A., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.04.015 · Cited by 519
Self-citationActivating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease
Flanagan, S. E., Haapaniemi, E., Russell, M. A., Caswell, R., Allen, H. L., De Franco, E., McDonald, T. J., Rajala, H., Ramelius, A., Barton, J., et al. (2014) · Nature Genetics · doi:10.1038/ng.3040 · Cited by 508
Oliveira, J. B., Bleesing, J. J., Dianzani, U., Fleisher, T. A., Jaffe, E. S., Lenardo, M. J., Rieux-Laucat, F., Siegel, R. M., Su, H. C., Teachey, D. T., et al. (2010) · Blood · doi:10.1182/blood-2010-04-280347 · Cited by 495
Treg and CTLA-4: Two intertwining pathways to immune tolerance
Walker, L. S. K. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.006 · Cited by 411
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex
Schwartz, J.-C. D., Zhang, X., Fedorov, A. A., Nathenson, S. G., & Almo, S. C. (2001) · Nature · doi:10.1038/35069112 · Cited by 349
Barzaghi, F., Passerini, L., & Bacchetta, R. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00211 · Cited by 325
The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency
Gámez-Díaz, L., August, D., Stepensky, P., Revel-Vilk, S., Seidel, M. G., Noriko, M., Morio, T., Worth, A. J. J., Blessing, J., Van de Veerdonk, F., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.09.025 · Cited by 285
Self-citationCD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
Friedline, R. H., Brown, D. S., Nguyen, H., Kornfeld, H., Lee, J., Zhang, Y., Appleby, M., Der, S. D., Kang, J., & Chambers, C. A. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081811 · Cited by 266
Alangari, A., Alsultan, A., Adly, N., Massaad, M. J., Kiani, I. S., Aljebreen, A., Raddaoui, E., Almomen, A.-K., Al-Muhsen, S., Geha, R. S., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.05.043 · Cited by 252
Self-citationCharbonnier, L.-M., Janssen, E., Chou, J., Ohsumi, T. K., Keles, S., Hsu, J. T., Massaad, M. J., Garcia-Lloret, M., Hanna-Wakim, R., Dbaibo, G., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.019 · Cited by 244
Self-citationBour‐Jordan, H., & Bluestone, J. A. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00775.x · Cited by 223
Spectrum of Phenotypes Associated with Mutations in LRBA
Alkhairy, O. K., Abolhassani, H., Rezaei, N., Fang, M., Andersen, K. K., Chavoshzadeh, Z., Mohammadzadeh, I., El-Rajab, M. A., Massaad, M., Chou, J., et al. (2016) · Journal of Clinical Immunology · doi:10.1007/s10875-015-0224-7 · Cited by 207
Self-citationIPEX, FOXP3 and regulatory T-cells: a model for autoimmunity
Ochs, H. D., Gambineri, E., & Torgerson, T. R. (2007) · Immunologic Research · doi:10.1007/s12026-007-0022-2 · Cited by 176
Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4
Zeißig, S., Petersen, B., Tomczak, M. F., Melum, E., Huc‐Claustre, E., Dougan, S. K., Laerdahl, J. K., Stade, B., Förster, M., Schreiber, S., et al. (2014) · Gut · doi:10.1136/gutjnl-2014-308541 · Cited by 146
Self-citationHou, T. Z., Verma, N., Wanders, J., Kennedy, A., Soskic, B., Janman, D., Halliday, N., Rowshanravan, B., Worth, A. J. J., Qasim, W., et al. (2017) · Blood · doi:10.1182/blood-2016-10-745174 · Cited by 112
Self-citationLRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia
Burns, S. O., Zenner, H. L., Plagnol, V., Curtis, J. W., Mok, K. Y., Eisenhut, M., Kumararatne, D. S., Döffinger, R., Thrasher, A. J., & Nejentsev, S. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.035 · Cited by 110
Hematopoietic stem cell transplantation for CTLA4 deficiency
Slatter, M. A., Engelhardt, K. R., Burroughs, L. M., Arkwright, P. D., Nademi, Z., Skoda‐Smith, S., Hagin, D., Kennedy, A., Barge, D., Flood, T. J., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.01.045 · Cited by 103
Self-citationAutoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation
Revel‐Vilk, S., Fischer, U., Keller, B., Nabhani, S., Gámez-Díaz, L. Y., Rensing‐Ehl, A., Gombert, M., Hönscheid, A., Saleh, H., Shaag, A., et al. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.04.007 · Cited by 93
Self-citationAtypical Manifestation of LRBA Deficiency with Predominant IBD-like Phenotype
Serwas, N. K., Kansu, A., Santos-Valente, E., Kuloğlu, Z., Demir, A. M., Yaman, A., Gámez-Díaz, L. Y., Artan, R., Sayar, E., Ensarı, A., et al. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000266 · Cited by 87
Self-citationSeidel, M. G., Hirschmugl, T., Gámez-Díaz, L. Y., Schwinger, W., Serwas, N. K., Deutschmann, A. J., Gorkiewicz, G., Zenz, W., Windpassinger, C., Grimbacher, B., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.048 · Cited by 71
Self-citationLRBA deficiency with autoimmunity and early onset chronic erosive polyarthritis
Lévy, E., Stolzenberg, M., Bruneau, J., Breton, S., Neven, B., Sauvion, S., Zarhrate, M., Nitschké, P., Fischer, A., Magérus, A., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.03.006 · Cited by 61
Schreiner, F., Plamper, M., Düker, G., Schönberger, S., Gámez-Díaz, L. Y., Grimbacher, B., Hilger, A. C., Gohlke, B. C., Reutter, H. M., & Woelfle, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3382 · Cited by 45
Self-citationA Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer
Hayakawa, S., Okada, S., Tsumura, M., Sakata, S., Ueno, Y., Imai, K., Morio, T., Ohara, O., Chayama, K., & Kobayashi, M. (2015) · Journal of Clinical Immunology · doi:10.1007/s10875-015-0221-x · Cited by 43
Self-citationA Successful HSCT in a Girl with Novel LRBA Mutation with Refractory Celiac Disease
Sarı, S., Doğu, F., Hwa, V., Haskoloğlu, Ş., Dauber, A. N., Rosenfeld, R. G., Polat, M., Kuloğlu, Z., Kansu, A., Dalgıç, B., et al. (2015) · Journal of Clinical Immunology · doi:10.1007/s10875-015-0220-y · Cited by 42
CTLA-4 haploinsufficiency in a patient with an autoimmune lymphoproliferative disorder
Kucuk, Z. Y., Charbonnier, L., McMasters, R. L., Chatila, T. A., & Bleesing, J. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.02.032 · Cited by 40
Self-citationVedolizumab as a successful treatment of CTLA-4–associated autoimmune enterocolitis
Navarini, A. A., Hruz, P. L., Berger, C. T., Hou, T. Z., Schwab, C., Gabrysch, A., Higgins, R., Frede, N., Sgier, B.-C. P., Kämpe, O., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.08.042 · Cited by 31
Self-citationHou, T. Z., Olbrich, P., Soto, J. M. L., Sánchez, B., Moreno, P. S., Borte, S., Stauss, H. J., Burns, S. O., Walker, L. S. K., Pan‐Hammarström, Q., et al. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.01.001 · Cited by 17
Self-citation
Cited by
Tangye, S. G., Al-Herz, W., Bousfiha, A., Chatila, T., Cunningham-Rundles, C., Etzioni, A., Franco, J. L., Holland, S. M., Klein, C., Morio, T., et al. (2020) · Journal of Clinical Immunology · doi:10.1007/s10875-019-00737-x · Cited by 1,210
Self-citationMoving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Wei, S. C., Meijers, W. C., Axelrod, M. L., Anang, N.-A. A. S., Screever, E. M., Wescott, E. C., Johnson, D. B., Whitley, E., Lehmann, L., Courand, P.-Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0856 · Cited by 290
Human inborn errors of immunity: An expanding universe
Notarangelo, L. D., Bacchetta, R., Casanova, J.-L., & Su, H. C. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb1662 · Cited by 276
Early-onset autoimmunity associated with SOCS1 haploinsufficiency
Hadjadj, J., Castro, C. N., Tusseau, M., Stolzenberg, M.-C., Mazerolles, F., Aladjidi, N., Armstrong, M., Ashrafian, H., Cutcutache, I., Ebetsberger-Dachs, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18925-4 · Cited by 156
Self-citation
Metadata
- Authors
- Schwab, C., Gabrysch, A., Olbrich, P., Patiño, V., Warnatz, K., Wolff, D., Hoshino, A., Kobayashi, M., Imai, K., Takagi, M., Dybedal, I., Haddock, J. A., Sansom, D. M., Lucena, J. M., Seidl, M., Schmitt-Graeff, A., Reiser, V., Emmerich, F., Frede, N., Bulashevska, A., Salzer, U., Schubert, D., Hayakawa, S., Okada, S., Kanariou, M., Kucuk, Z. Y., Chapdelaine, H., Petruzelkova, L., Sumnik, Z., Sediva, A., Slatter, M., Arkwright, P. D., Cant, A., Lorenz, H.-M., Giese, T., Lougaris, V., Plebani, A., Price, C., Sullivan, K. E., Moutschen, M., Litzman, J., Freiberger, T., van de Veerdonk, F. L., Recher, M., Albert, M. H., Hauck, F., Seneviratne, S., Pachlopnik Schmid, J., Kolios, A., Unglik, G., Klemann, C., Speckmann, C., Ehl, S., Leichtner, A., Blumberg, R., Franke, A., Snapper, S., Zeissig, S., Cunningham-Rundles, C., Giulino-Roth, L., Elemento, O., Dückers, G., Niehues, T., Fronkova, E., Kanderová, V., Platt, C. D., Chou, J., Chatila, T. A., Geha, R., McDermott, E., Bunn, S., Kurzai, M., Schulz, A., Alsina, L., Casals, F., Deyà-Martinez, A., Hambleton, S., Kanegane, H., Taskén, K., Neth, O., & Grimbacher, B.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 142
- Issue
- 6
- Pages
- 1932-1946
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2801254160
- Cited by
- 438
- References
- 41
- FWCI
- 17.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.